tiprankstipranks
Advertisement
Advertisement

ARCT Stock Latest News

Arcturus Maintained at Buy as Advancing Pipeline and Strong Cash Position Support Unchanged $23 Price Target
RatingsArcturus Maintained at Buy as Advancing Pipeline and Strong Cash Position Support Unchanged $23 Price Target
2d ago
ARCT
Arcturus Therapeutics price target lowered to $20 from $21 at Canaccord
PremiumThe Fly
Arcturus Therapeutics price target lowered to $20 from $21 at Canaccord
4d ago
ARCT
Arcturus Therapeutics reports Q2 EPS (84c), consensus ($1.03)
PremiumThe Fly
Arcturus Therapeutics reports Q2 EPS (84c), consensus ($1.03)
5d ago
ARCT
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
8d ago
ARCT
Arcturus Therapeutics: Buy Rating Backed by Advancing mRNA Programs and De-Risked CF Manufacturing Partnership
PremiumRatings
Arcturus Therapeutics: Buy Rating Backed by Advancing mRNA Programs and De-Risked CF Manufacturing Partnership
1M ago
ARCT
Arcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth
PremiumThe FlyArcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth
1M ago
TMO
ARCT
Arcturus Therapeutics Announces Thermo Fisher mRNA Partnership
Premium
Company Announcements
Arcturus Therapeutics Announces Thermo Fisher mRNA Partnership
1M ago
8K
ARCT
Arcturus announces collaboration with Thermo Fisher to advance ARCT-032
Premium
The Fly
Arcturus announces collaboration with Thermo Fisher to advance ARCT-032
1M ago
TMO
ARCT
Arcturus Therapeutics initiated with a Buy at Freedom Broker
PremiumThe Fly
Arcturus Therapeutics initiated with a Buy at Freedom Broker
1M ago
ARCT
Arcturus Shareholders Back Board, Pay, and Auditor
PremiumCompany Announcements
Arcturus Shareholders Back Board, Pay, and Auditor
2M ago
8K
ARCT
Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn
PremiumCompany Announcements
Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn
3M ago
ARCT
Myles Minter Reiterates Buy on Arcturus Therapeutics, Highlighting Long-Term Upside Despite More Conservative Near-Term Outlook
PremiumRatings
Myles Minter Reiterates Buy on Arcturus Therapeutics, Highlighting Long-Term Upside Despite More Conservative Near-Term Outlook
3M ago
ARCT
ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
PremiumRatingsARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
3M ago
ARCT
Arcturus Therapeutics Signals Progress Amid Revenue Slip
Premium
Company Announcements
Arcturus Therapeutics Signals Progress Amid Revenue Slip
3M ago
ARCT
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
Premium
Ratings
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
3M ago
ARCT
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
PremiumCompany Announcements
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
3M ago
8K
ARCT
Arcturus Therapeutics reports Q1 EPS (95c), consensus ($1.01)
PremiumThe Fly
Arcturus Therapeutics reports Q1 EPS (95c), consensus ($1.01)
3M ago
ARCT
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
ARCT
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
PremiumMarket News
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
4M ago
WGS
ARCT
Arcturus Therapeutics initiated with a Buy at B. Riley
PremiumThe FlyArcturus Therapeutics initiated with a Buy at B. Riley
5M ago
ARCT
Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord
Premium
The Fly
Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord
5M ago
ARCT
Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
Premium
Company Announcements
Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
5M ago
ARCT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >